Publisher
Springer Science and Business Media LLC
Reference78 articles.
1. US Food and Drug Administration. Biological product definitions. 2020. https://www.fda.gov/media/108557/download. Accessed 6 Feb 2020
2. Liu Y, Yang M, Garg V, Wu EQ, Wang J, Skup M. Economic impact of non-medical switching from originator biologics to biosimilars: a systematic literature review. Adv Ther. 2019;36(8):1851–77.
3. Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals. 2016;44(4):257–66.
4. Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463–78.
5. Otto ESA, Schrader U. Rapid growth in biopharma: challenges and opportunities. 2014. https://www.mckinsey.com/~/media/McKinsey/Industries/Healthcare%20Systems%20and%20Services/Our%20Insights/Rapid%20growth%20in%20biopharma/Rapid%20growth%20in%20biopharma%20Challenges%20and%20opportunities.ashx. Accessed 6 Feb 2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献